Navigating ANVISA in Brazil: Pure Global Explains the Surprising GMP Rule for Class I Medical Devices in LATAM episode artwork

EPISODE · Sep 6, 2025 · 3 MIN

Navigating ANVISA in Brazil: Pure Global Explains the Surprising GMP Rule for Class I Medical Devices in LATAM

from LATAM MedTech Insights

This episode of LATAM MedTech Insights tackles a critical question for manufacturers entering Brazil: Is a Good Manufacturing Practice (GMP) certificate really required for low-risk, Class I medical devices? We explore the common misconceptions surrounding ANVISA's RDC 751/2022 regulation and the simplified *notificação* registration pathway. Many companies assume the lack of an upfront certificate submission means compliance is optional. This can be a costly mistake. We reveal how ANVISA's post-market surveillance can place your market access at risk if you're not prepared, and discuss how programs like MDSAP can be a strategic asset for demonstrating compliance. **A Case Study in Risk:** Imagine your startup's Class I device is successfully launched in Brazil via the "easy" *notificação* route. Six months later, ANVISA announces a surprise inspection of your facility. Are you confident your Quality Management System is fully B-GMP compliant right now? If not, you face immediate product withdrawal, fines, and reputational damage. This episode tells you how to avoid that scenario. **Key Takeaways From This Episode:** - Do all device classes truly need a B-GMP certificate before registering in Brazil? - What is the crucial difference between compliance and submission under RDC 751/2022? - Why can the simplified *notificação* pathway for Class I devices become a regulatory trap? - How can a post-market surveillance audit jeopardize your entire Brazilian market presence? - What is the one program that can significantly streamline your ANVISA compliance process? - Is your Quality Management System truly ready for an unannounced ANVISA inspection today? - What is the real role of the Medical Device Single Audit Program (MDSAP) in Brazil? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as your local representative, develop regulatory strategy, and ensure ongoing compliance in over 30 markets, including Brazil. Don't let regulatory surprises derail your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can secure your market access.

Episode metadata supplied by the publisher feed · Published Sep 6, 2025

Embed this episode

NOW PLAYING

Navigating ANVISA in Brazil: Pure Global Explains the Surprising GMP Rule for Class I Medical Devices in LATAM

0:00 3:21

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of LATAM MedTech Insights?

This episode is 3 minutes long.

When was this LATAM MedTech Insights episode published?

This episode was published on September 6, 2025.

Can I download this LATAM MedTech Insights episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!